- RTRX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $17.6 million.
- RTRX has traded 44,412 shares today.
- RTRX is trading at a new lifetime high.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in RTRX with the Ticky from Trade-Ideas. See the FREE profile for RTRX NOW at Trade-Ideas More details on RTRX: Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious, catastrophic, or rare diseases. RTRX has a PE ratio of 116. Currently there are 2 analysts that rate Retrophin a buy, no analysts rate it a sell, and none rate it a hold. The average volume for Retrophin has been 528,800 shares per day over the past 30 days. Retrophin has a market cap of $1.1 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.01 and a short float of 9.8% with 6.58 days to cover. Shares are up 164.7% year-to-date as of the close of trading on Wednesday. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Retrophin as a sell. The area that we feel has been the company's primary weakness has been its generally higher debt management risk. Highlights from the ratings report include:
- Despite currently having a low debt-to-equity ratio of 0.50, it is higher than that of the industry average, inferring that management of debt levels may need to be evaluated further. Regardless of the somewhat mixed results with the debt-to-equity ratio, the company's quick ratio of 1.32 is sturdy.
- Compared to other companies in the Biotechnology industry and the overall market, RETROPHIN INC's return on equity significantly trails that of both the industry average and the S&P 500.
- Net operating cash flow has increased to -$7.33 million or 25.21% when compared to the same quarter last year. Despite an increase in cash flow of 25.21%, RETROPHIN INC is still growing at a significantly lower rate than the industry average of 155.59%.
- RETROPHIN INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, RETROPHIN INC reported poor results of -$6.15 versus -$2.27 in the prior year. This year, the market expects an improvement in earnings ($0.29 versus -$6.15).
- The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Biotechnology industry. The net income increased by 152.3% when compared to the same quarter one year prior, rising from -$75.74 million to $39.66 million.
- You can view the full Retrophin Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.